Research programme: anti-complement component C3 proteases - Catalyst Biosciences

Drug Profile

Research programme: anti-complement component C3 proteases - Catalyst Biosciences

Alternative Names: anti-C3 protease - Catalyst Biosciences; CB 2782

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Catalyst Biosciences
  • Developer Catalyst Biosciences; Mosaic Biosciences
  • Class Peptide hydrolases
  • Mechanism of Action Complement C3 inhibitors; Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry age-related macular degeneration; Retinal disorders

Highest Development Phases

  • Preclinical Dry age-related macular degeneration; Retinal disorders
  • Discontinued Delayed graft function; Inflammation

Most Recent Events

  • 31 Oct 2017 Catalyst Biosciences and Mosaic Biosciences enter into collaboration to develop intravitreal anti-complement component C3 proteases for the treatment of Dry-age related macular degeneration and Retinal disorders
  • 24 Oct 2017 Preclinical trials in Dry age-related macular degeneration in USA (Intravitreous)
  • 24 Oct 2017 Preclinical trials in Retinal disorders in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top